Scaff10-8

Scaff10-8 (1 h) potently inhibits the interaction between recombinant AKAP-Lbc/DHPH and RhoA in an HTRF assay with an IC₅₀ of 34.1 μM^[1].
Scaff10-8 inhibits the interaction between recombinant AKAP-Lbc DH domain and RhoA in an Alpha Screen assay with an IC₅₀ of 42 μM^[1].
Scaff10-8 (1 h) binds directly to recombinant 647-RhoA with a K_d of 20 μM, as measured by MST^[1].
Scaff10-8 binds specifically to both GDP-bound and GTPγS-bound recombinant GST-RhoA, with K_d values of 20 μM and 38 μM, respectively^[1].
Scaff10-8 (30-100 μM; 24-72 h) is not cytotoxic to primary IMCD, MCD4, HEK293, MCF7, or H9C2 cells^[1].
Scaff10-8 (30 μM; 1 h) inhibits RhoA activity in primary IMCD cells^[1].
Scaff10-8 (30 μM; 1 h) does not affect the activity of Cdc42 or Rac1 in primary IMCD cells^[1].
Scaff10-8 (30 μM; 1 h) promotes the redistribution of AQP2 to the periphery of primary IMCD cells and depolymerizes F-actin^[1].
Scaff10-8 (30 μM; 1-24 h) does not promote the insertion of AQP2 into the plasma membrane of primary IMCD cells^[1].
Scaff10-8 (30-100 μM; 24 h) selectively inhibits AKAP-Lbc-mediated RhoA activation in HEK293 cells, with no effect on LARG or PDZ-RhoGEF-mediated RhoA activation, when treated at 30 or 100 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.